Skip to content

Available 24/7 for Urgent On-Site or Virtual Consulting

  • (208) 971-6430
  • [email protected]

FDA Inspections

Consulting and Compliance

  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
Contact Us
  • A scientist wearing a lab coat, hairnet, mask, and glasses works on a computer displaying a 3D model of a laboratory. The setting illustrates virtual lab environments supporting GxP compliance in pharmaceutical and biotech industries.
    Inspections

    GxP Compliance in Virtual Laboratories: Key Challenges and Best Practices

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The shift to virtual laboratories presents immense opportunities for innovation in the life sciences industry, but it also introduces complex regulatory challenges. Achieving GxP compliance for virtual laboratories is critical for ensuring product quality, safety, and efficacy. This comprehensive guide explores the primary hurdles, such as ensuring data integrity, validating cloud-based software, and managing remote teams, that companies face. More importantly, it outlines actionable best practices and robust strategies to build a compliant digital framework from the ground up, helping you avoid common pitfalls that can lead to severe regulatory actions. By understanding these dynamics, you can harness the power of virtual environments while upholding the highest standards of quality and compliance.

    Read More GxP Compliance in Virtual Laboratories: Key Challenges and Best PracticesContinue

  • Scientist in a lab coat works on a computer displaying AI graphics, surrounded by test tubes and a microscope in a modern pharmaceutical lab.
    Inspections

    Using AI in Pharmaceutical Quality Control: Opportunities & Compliance Risks

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The integration of Artificial Intelligence (AI) is revolutionizing pharmaceutical quality control, offering unprecedented efficiency and accuracy. From predictive maintenance to real-time process monitoring, AI promises to reduce human error and enhance product consistency. However, this powerful technology also introduces significant compliance challenges. Navigating data integrity, model validation, and evolving regulatory expectations is crucial to avoid serious FDA actions. This article explores the key opportunities and compliance risks associated with AI in pharmaceutical quality control, guiding companies on how to innovate responsibly while upholding the highest standards of safety and quality in a regulated environment.

    Read More Using AI in Pharmaceutical Quality Control: Opportunities & Compliance RisksContinue

  • Close-up of a person holding an FDA warning letter addressed to a medical device company, with a blood pressure monitor and pen on the desk.
    Warning Letters

    Top Reasons Medical Device Companies Receive FDA Warning Letters

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Receiving an FDA warning letter can severely impact a medical device company’s operations, reputation, and financial stability. These letters signify serious regulatory violations that were not adequately addressed after an inspection. Understanding the common pitfalls is the first step toward building a robust compliance framework. This article explores the top reasons medical device companies receive warning letters, from inadequate CAPA systems and poor complaint handling to failures in design and process controls. Learn how to strengthen your quality system and maintain a constant state of inspection readiness.

    Read More Top Reasons Medical Device Companies Receive FDA Warning LettersContinue

  • Pharmaceutical worker in protective gear inspecting a tray of tablets inside a clean, sterile GMP-compliant manufacturing facility.
    Inspections

    A Practical Guide to GMP Compliance for OTC Pharmaceutical Manufacturers

    ByFDA Inspections Team September 25, 2025September 25, 2025

    This definitive guide provides a practical roadmap to achieving and maintaining GMP compliance for OTC pharmaceutical manufacturers. We delve deep into the core tenets of 21 CFR Part 211, from establishing a robust Quality Management System to navigating personnel training, facility management, and meticulous documentation. Learn how to prepare for FDA inspections, avoid common 483 observations, and build a culture of quality that ensures product safety, efficacy, and consumer trust.

    Read More A Practical Guide to GMP Compliance for OTC Pharmaceutical ManufacturersContinue

  • Doctor in a white coat reviews an FDA pre-approval inspection checklist at his desk, holding a pen with focus beside a laptop in an office.
    Inspections

    FDA Pre-Approval Inspection Checklist: How to Prepare and What to Expect

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The FDA Pre-Approval Inspection (PAI) is arguably the most critical regulatory milestone for any pharmaceutical company seeking to bring a new product to market. It’s not just another audit; it’s a comprehensive validation of your manufacturing process and a direct assessment of your readiness to produce a safe and effective drug. Failing a PAI can lead to significant delays and financial loss. This guide provides a definitive FDA pre-approval inspection checklist to help you prepare and succeed.

    Read More FDA Pre-Approval Inspection Checklist: How to Prepare and What to ExpectContinue

  • Person on video call with FDA inspector, holding supplement bottle for virtual inspection, with quality control checklist on desk.
    Inspections

    What to Expect in Virtual FDA Inspections for Dietary Supplement Facilitie

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The FDA is increasingly using virtual inspections for dietary supplement facilities. This shift demands a new approach to compliance. Our in-depth guide explains what to expect from these Remote Regulatory Assessments (RRAs), how to prepare your technology and documentation, and strategies for navigating live-streamed tours and interviews. Learn how to maintain cGMP standards, avoid common pitfalls, and ensure your facility is ready for a seamless virtual audit from the FDA.

    Read More What to Expect in Virtual FDA Inspections for Dietary Supplement FacilitieContinue

  • how to respond to FDA Warning Letters
    Warning Letters

    How to Respond to an FDA Warning Letter: A Complete Guide for Manufacturers

    Byplwertalik July 5, 2025July 6, 2025

    Receiving an FDA Warning Letter is one of the most serious regulatory events that can occur for any manufacturer in the United States. It is not merely a slap on the wrist—it is a formal, public notice that the U.S. Food and Drug Administration has determined your facility or your products are in significant violation…

    Read More How to Respond to an FDA Warning Letter: A Complete Guide for ManufacturersContinue

  • FDA Observations for Dietary Supplement manufacturers
    Inspections

    Most Common FDA 483 Observations for Dietary Supplement Manufacturers (With Real Examples)

    Byplwertalik July 5, 2025July 6, 2025

    Get an in-depth look at the most common FDA 483 observations for dietary supplement manufacturers, with real-world inspection examples and practical tips to stay audit-ready.

    Read More Most Common FDA 483 Observations for Dietary Supplement Manufacturers (With Real Examples)Continue

  • Types of FDA inspections
    Inspections

    Types of FDA Inspections: What You Need to Know (2025 Guide)

    Byplwertalik July 5, 2025July 6, 2025

    Learn about the main types of FDA inspections, from pre-approval to for-cause and routine GMP checks. This essential guide explains what to expect, how to prepare, and how to stay compliant. Includes official FDA resources and practical tips.

    Read More Types of FDA Inspections: What You Need to Know (2025 Guide)Continue

  • Top 10 FDA 483 Observations of 2024—and How to Avoid Them in 2025
    Actions

    Top 10 FDA 483 Observations of 2024—and How to Avoid Them in 2025

    Byplwertalik May 26, 2025July 6, 2025

    As regulatory pressures grow and the US Food and Drug FDA refines its inspection protocols, companies in the life sciences and healthcare industries must stay one step ahead. Each year, the agency releases insights from its FDA Form 483 observations—warning flags issued after inspections. In this post, we analyze the top 10 FDA 483 observations…

    Read More Top 10 FDA 483 Observations of 2024—and How to Avoid Them in 2025Continue

Page navigation

Previous PagePrevious 1 … 10 11 12 13 Next PageNext

FDA Inspections

Your trusted partner for FDA compliance and inspection readiness. With former ex-FDA’ers  on our team, we provide the expertise and confidence you need to succeed.

  • (208) 971-6430
  • [email protected]

Services

  • Pre-Inspection Prep
  • On-Site Support
  • CAPA Development
  • Staff Training
  • Documentation
  • Emergency Support

Industries

  • Pharmaceuticals
  • Medical Devices
  • Biotechnology
  • Food & Beverage
  • Cosmetics
  • Clinical Research
© 2024 FDA Inspections. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • Disclaimer
THE IMMERSIVE FDA INSPECTION EXPERIENCE →
WARNING LETTERS 483 OBSERVATIONS